通过学习型健康系统模式实现胰腺切除术后无阿片类药物出院
这项队列研究纳入832例连续接受胰腺切除术的成人患者,分析2次迭代的风险分层胰腺切除术临床路径(RSPCP)更新对住院和出院阿片类药物用量的影响。结果显示,住院总口服吗啡当量(OME)中位数从V1的290 mg降至V3的129 mg,出院OME中位数从150 mg降至0 mg,无阿片类药物出院比例从7.2%升至52.5%,各队列中位疼痛评分保持在3或以下。
要点
- RSPCP迭代更新与住院及出院阿片类药物用量显著降低相关(P < .001)。
- V3队列无阿片类药物出院比例达52.5%(126/240),77.9%(187/240)出院时OME≤50 mg。
- 各队列中位疼痛评分保持在3或以下,出院后处方续配请求无差异。
核心结论
- 在本次队列研究中,中位住院总OME减半,中位出院OME降至零,与可被其他医院自由采用的学习型健康系统迭代阿片类药物减量模型相关。
- 这些发现提示,采用这种零成本蓝图,胰腺切除术和其他大型癌症手术后的无阿片类药物出院是现实且可行的。
研究设计与样本
- 这项队列研究纳入2016年10月至2022年4月在一家城市综合癌症中心连续接受胰腺切除术的832例成人患者,分为3个序贯路径队列。
- V1队列为2016年10月1日至2019年1月31日(n=363),V2队列为2019年2月1日至2020年10月31日(n=229),V3队列为2020年11月1日至2022年4月30日(n=240)。
主要发现
- 早期非阿片类药物组合给药从V1(对乙酰氨基酚320例[88.2%]、塞来昔布或抗炎药98例[27.0%]、美索巴莫267例[73.6%])增加至V3(分别为236例[98.3%]、163例[67.9%]、238例[99.2%];P < .001)。
- 住院总OME中位数从V1的290 mg(IQR,157-468 mg)降至V2的184 mg(IQR,103-311 mg)再降至V3的129 mg(IQR,75-206 mg)(P < .001)。
- 出院OME中位数从V1的150 mg(IQR,100-225 mg)降至V2的25 mg(IQR,0-100 mg)再降至V3的0 mg(IQR,0-50 mg)(P < .001)。
- 无阿片类药物出院患者比例从V1的7.2%(26/363)增加至V3的52.5%(126/240)(P < .001),V3中187/240(77.9%)出院时OME≤50 mg。
- 各队列中位疼痛评分保持在3或以下,出院后处方续配请求无差异;按开放手术和微创手术分层的亚组分析显示两组结果相似。
关键数值与推荐
- V2更新了患者和外科医生教育材料,限制静脉阿片类药物,建议使用3药非阿片类药物组合(对乙酰氨基酚、塞来昔布、美索巴莫),并实施5倍乘数(最后24小时口服吗啡当量[OME]乘以5)计算出院用量。
- V3要求恢复室默认使用非阿片类药物组合,并计划术后第1天转换为口服药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Postoperative opioid overprescribing leads to persistent opioid use and excess pills at risk for misuse and diversion. A learning health system paradigm using risk-stratified pancreatectomy clinical pathways (RSPCPs) may lead to reduction in inpatient and discharge opioid volume. OBJECTIVE: To analyze the outcomes of 2 iterative RSPCP updates on inpatient and discharge opioid volumes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 832 consecutive adult patients at an urban comprehensive cancer center who underwent pancreatic resection between October 2016 and April 2022, comprising 3 sequential pathway cohorts (version [V] 1, October 1, 2016, to January 31, 2019 [n = 363]; V2, February 1, 2019, to October 31, 2020 [n = 229]; V3, November 1, 2020, to April 30, 2022 [n = 240]). EXPOSURES: After V1 of the pathway established a baseline and reduced length of stay (n = 363), V2 (n = 229) updated patient and surgeon education handouts, limited intravenous opioids, suggested a 3-drug (acetaminophen, celecoxib, methocarbamol) nonopioid bundle, and implemented the 5×-multiplier (last 24-hour oral morphine equivalents [OME] multiplied by 5) to calculate discharge volume. Pathway version 3 (n = 240) required the nonopioid bundle as default in the recovery room and scheduled conversion to oral medications on postoperative day 1. MAIN OUTCOMES AND MEASURES: Inpatient and discharge opioid volume in OME across the 3 RSPCPs were compared using nonparametric testing and trend analyses. RESULTS: A total of 832 consecutive patients (median [IQR] age, 65 [56-72] years; 410 female [49.3%] and 422 male [50.7%]) underwent 541 pancreatoduodenectomies, 285 distal pancreatectomies, and 6 other pancreatectomies. Early nonopioid bundle administration increased from V1 (acetaminophen, 320 patients [88.2%]; celecoxib or anti-inflammatory, 98 patients [27.0%]; methocarbamol, 267 patients [73.6%]) to V3 (236 patients [98.3%], 163 patients [67.9%], and 238 patients [99.2%], respectively; P < .001). Total inpatient OME decreased from a median 290 mg (IQR, 157-468 mg) in V1 to 184 mg (IQR, 103-311 mg) in V2 to 129 mg (IQR, 75-206 mg) in V3 (P < .001). Discharge OME decreased from a median 150 mg (IQR, 100-225 mg) in V1 to 25 mg (IQR, 0-100 mg) in V2 to 0 mg (IQR, 0-50 mg) in V3 (P < .001). The percentage of patients discharged opioid free increased from 7.2% (26 of 363) in V1 to 52.5% (126 of 240) in V3 (P < .001), with 187 of 240 (77.9%) in V3 discharged with 50 mg OME or less. Median pain scores remained 3 or lower in all cohorts, with no differences in postdischarge refill requests. A subgroup analysis separating open and minimally invasive surgical cases showed similar results in both groups. CONCLUSIONS AND RELEVANCE: In this cohort study, the median total inpatient OME was halved and median discharge OME reduced to zero in association with a learning health system model of iterative opioid reduction that is freely adaptable by other hospitals. These findings suggest that opioid-free discharge after pancreatectomy and other major cancer operations is realistic and feasible with this no-cost blueprint.
引用
- Boyev A, Jain AJ, Newhook TE, et al. Opioid-Free Discharge After Pancreatic Resection Through a Learning Health System Paradigm. JAMA Surg. 2023. PMID: 37672236. doi:10.1001/jamasurg.2023.4154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。